Advanced searches left 3/3

Alzheimer's Disease - DOAJ

Summarized by Plex Scholar
Last Updated: 14 April 2022

* If you want to update the article please login/register

Integrated approach on UPLC-QTOF/MS based active plasma component and metabolomics analysis of Gan Mai Da Zao decoction on the treatment of Alzheimer's disease in rats plasma and urine

The results revealed 9 active components in ESI+ and 3 active components of ESI+ of Gan-Mai-Zao decoction in blood were identified, in addition to the Gan-Mai-Dao decoction, and Gan-Mai-Zao decoction improved the learning and memory performance as well as pathological damage in Alzheimer's disease rats. After recovering from a Gan-Mai-Da-Zao decoction program, 57 plasma metabolites and 21 urine metabolites were returned to normal in Alzheimer's disease model group. This research may lead to a deeper understanding of Alzheimer's disease-associated metabolic profile as well as the therapeutic mechanism of Gan-Mai-Da-Zao's Alzheimer's disease decoction.

Source link: https://doi.org/10.1016/j.arabjc.2022.103879


A survey of smartphone and interactive video technology use by participants in Alzheimer's disease research: Implications for remote cognitive assessment

Abstract Abstract: Participants from a longitudinal cohort study were polled to determine the practical benefits of remote cognitive assessment. Methods The University of California San Diego Alzheimer's Disease Research Center's active participants and informants were invited to complete a nine-question survey evaluating technology usage/use and readiness to perform cognitive assessments remotely. Device access was higher among those with normal cognition or cognitive impairment than those with dementia, as was the ability to perform remote cognitive assessments. Latinos were less likely than non-Latinos to have internet or device connectivity, but they were similarly able to perform remote testing.

Source link: https://doi.org/10.1002/dad2.12188


Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease

Abstract Synaptic dysfunction and degeneration are two of Alzheimer's disease's oldest events and the best predictors of cognitive decline in Alzheimer's disease. Therefore, detection and validation of biomarkers that mimic synaptic degeneration are crucial for prognostic biomarkers. In two cross-sectional studies involving AD and controls, solid phase extraction and parallel reaction monitoring mass spectrometry were used to quantify 17 synaptic proteins in CSF.

Source link: https://doi.org/10.1002/dad2.12179


Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease

Abstract This research examined acute changes in odor identification following atropine nasal spray challenge and an 8-week improvement in odor detection as a predictor of long-term improvement in patients with mild to moderate Alzheimer's disease patients receiving open-label cholinesterase inhibitor therapy. Results In 21 participants, acute atropine-induced decline in UPSIT was not related to improvements in the Alzheimer's Disease Assessment Scale Cognitive Subscale or Selective Reminding Test, but not related to change in the Alzheimer's Disease Assessment Scale. The decline in cognitive endurance over the past 52 weeks was shown by the decrease in odor identification results from baseline to week 8.

Source link: https://doi.org/10.1002/dad2.12158


Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease

Abstract: Down syndrome, a genetic variant of early onset Alzheimer's disease, is the most common outcome measure for prevention trials targeting pre-dementia stages. Methods We used cognitive test results from several longitudinal aging studies around the world, from 312 people with dementia to select composites that were sensitive to change over time. Discussion We have found a composite that is sensitive to early decline and, thus, could be useful as an outcome measure in trials to prevent or delay AD symptoms in DS.

Source link: https://doi.org/10.1002/dad2.12184


Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease

Abstract Abstract: Unsupervised digital cognitive testing is an effective way to detect subtle cognitive decline in preclinical Alzheimer's disease. Here, we discuss the Boston Remote Assessment for Neurocognitive Health's (British) Health Study, as well as in-person cognitive testing and amyloid/tau burdens. Methods BRANCH is web-based, self-guided, and it evaluates memory functions in AD. With elevated amyloid and entorhinal tau, the lower BRANCH score was correlated with greater amyloid and entorhinal tau. Discussion BRANCH consistently captures useful cognitive data remotely, implying that it can be used as a digital cognitive marker early in the AD process.

Source link: https://doi.org/10.1002/dad2.12243


CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status

Abstract tangle etiology is a summary of Alzheimer's disease-related changes in tau and phosphorylated tau, according to the author's chromo. These tau tangle etiology chemistry can help increase AD/MCI prediction accuracy and can provide insight into tau tangle etiology.

Source link: https://doi.org/10.1002/dad2.12167


Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values

Abstract Introduction: Random deviations in cerebrospinal fluid biomarker measurements can lead to bias in Alzheimer's disease studies. Methods A total of 792 CSF samples from 528 participants were tested in three batches for 12 biomarkers and 3 biomarker ratios in three batches. To convert CSF values between batches, standardized linear models were used. Results We found statistically significant batch differences for all biomarkers and ratios, except that the neurofilament light was comparable between batches 1 and 2.

Source link: https://doi.org/10.1002/dad2.12194


A profile of brain reserve in adults at genetic risk of Alzheimer's disease

Abstract The apolipoprotein E 4 allele is the most common risk factor for Alzheimer's disease in the United States. Our aim was to identify the psychosocial brain strategies that could eliminate the negative effects of APOE 4 on cognition, which could have ramifications for AD diagnosis and treatment trial selection. Measures of regional brain mass and cognitive function were determined. APOE and CDR on the left precuneus and bilateral superior frontal volumes were highly active. Discussion This pattern of preserved brain morphology in cognitively healthy 4 carriers with minimal medial temporal volume is consistent with brain reserve theory.

Source link: https://doi.org/10.1002/dad2.12208

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions